Guest editorial| Volume 27, ISSUE 1, P1-3, May 1997

Cardiovascular disease prevention in postmenopausal women: a clinician's perspective

      This paper is only available as a PDF. To read, Please Download here.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Sacks FM
        • Pfeffer MA
        • Lemuel AM
        • et al.
        The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
        New Engl J Med. 1996; 335: 1001-1009
        • Scandanavian Simvastatin Survival Study Group
        Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandanavian Simvastatin Survival Study (4S).
        Lancet. 1994; 344: 1383-1389
        • Jacobs D
        • Blackburn H
        • Higgins M
        • et al.
        Report of the conference on low blood cholesterol: mortality associations.
        Circulation. 1992; 86: 1046-1060
        • Kannel WB
        Metabolic risk factors for coronary heart disease in women perspective from the Framingham Study.
        Am Heart J. 1987; 114: 413-419
        • Jacobs Jr, DR
        • Mebane IL
        • Bangdiwala SI
        • et al.
        High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow up study of the Lipids Research Clinics Prevalence Study.
        Am J Epidemiol. 1990; 131: 32-47
        • Bush TL
        • Barrett-Connor E
        • Cowen LD
        • et al.
        Cardiovascular mortality in non-contraceptive use of estrogen in women: results from the Lipid Research Clinic Program Follow-up Study.
        Circulation. 1987; 75: 1102-1109
        • Stampfer MJ
        • Colditz GA
        • Willett WC
        • et al.
        Postmenopausal estrogen therapy and cardiovascular disease: 10-year follow-up from the Nurses' Health Study.
        New Engl J Med. 1991; 325: 756-762
        • Sullivan JM
        • Vander Zwaag R
        • Hughes JP
        • et al.
        Estrogen replacement and coronary artery disease.
        Arch Intern Med. 1990; 150: 2557-2562
        • Lindsay R
        • Bush TL
        • Grady D
        • Speroff L
        • Lobo RA
        Estrogen Replacement in Menopause.
        J Clin Endocrinol Metab. 1996; 81: 3829-3838
        • Darling GM
        • Johns JA
        • Hamer AWF
        • Davis SR
        The effect of combined oestrogen and progesterone on lipid levels in postmenopausal women with hypercholesterolemia.
        in: Proceedings of the 10th International Congress of Endocrinology, San Francisco, USA1996
        • Grodstein F
        • Stampfer MJ
        • Manson JE
        • et al.
        Postmenopausal estrogen and progestin and the risk of cardiovascular disease.
        New Engl J Med. 1996; 335: 453-461
        • Lobo RA
        Clinical Review 27: effects of hormone replacement on lipids and lipoproteins in postmenopausal women.
        J Clin Endocrinol Metab. 1991; 73: 925-930
        • Farish E
        • Spowart K
        • Barnes JF
        • et al.
        Effects of postmenopausal hormone replacement therapy on lipoproteins including lipoprotein (a) and LDL subfractions.
        Atherosclerosis. 1996; 126: 77-84
        • Farish E
        • Fletcher CD
        • Hart DM
        • et al.
        The effects of conjugated equine oestrogens with and without a cyclic progestogen on lipoproteins and HDL subfractions in postmenopausal women.
        Acta Endocrinol. 1986; 113: 123-128
        • Sarrel PM
        Blood flow.
        in: Lobo TA Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. Raven Press, New York1994: 251-262
        • Draper MW
        • Flowers DE
        • Huster WJ
        • et al.
        A controlled trial, of raloxifene (LY 139 481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women.
        J Bone Miner Res. 1996; 11: 835-842